| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 15% | +37.3% | $11.4M | $3.63M | 7.86M | +46.7% | Lynx1 Capital Management LP | 30 Jun 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 9.99% | $8.42M | 5.26M | BVF PARTNERS L P/IL | 31 Mar 2025 | |||
| K2 HealthVentures Equity Trust LLC | 6.9% | $5.76M | 3.6M | K2 HealthVentures Equity Trust LLC | 31 Dec 2024 | |||
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.13% | $5.6M | 3.5M | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| Adage Capital Management, L.P. | 2.52% | $1.96M | 1.35M | Adage Capital Management, L.P. | 30 Jun 2025 | |||
| BlackRock, Inc. | 1.8% | -72% | $1.48M | -$2.88M | 958K | -66.1% | BlackRock, Inc. | 30 Jun 2025 |
| EcoR1 Capital, LLC | 1.3% | $1.06M | 663K | EcoR1 Capital, LLC | 31 Mar 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 34.6M | $62.9M | -$1.89M | $1.82 | 72 |
| 2025 Q2 | 35.7M | $51.8M | -$5.88M | $1.45 | 79 |
| 2025 Q1 | 40.1M | $55.4M | -$2.86M | $1.38 | 92 |
| 2024 Q4 | 41.5M | $126M | -$5.92M | $3.04 | 87 |
| 2024 Q3 | 41.8M | $208M | +$257K | $4.98 | 86 |
| 2024 Q2 | 41.4M | $242M | +$40.5M | $5.85 | 78 |
| 2024 Q1 | 34.3M | $272M | +$19.1M | $7.94 | 65 |
| 2023 Q4 | 31.9M | $186M | +$7.21M | $5.83 | 54 |
| 2023 Q3 | 28.6M | $73.2M | +$2.18M | $2.56 | 32 |
| 2023 Q2 | 28M | $69.9M | +$45.8M | $2.50 | 28 |
| 2023 Q1 | 9.67M | $20.3M | +$610K | $2.10 | 28 |
| 2022 Q4 | 9.52M | $14.8M | -$121K | $1.55 | 28 |
| 2022 Q3 | 9.51M | $29M | -$531K | $3.05 | 24 |
| 2022 Q2 | 9.68M | $30.4M | +$1.53M | $3.14 | 23 |
| 2022 Q1 | 9.41M | $26.3M | -$1.5M | $2.80 | 24 |
| 2021 Q4 | 9.86M | $44.4M | -$2.46M | $4.50 | 28 |
| 2021 Q3 | 9.5M | $78.2M | +$78.2M | $8.34 | 25 |